Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar of Lucentis (ranibizumab) in the US

 Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar of Lucentis (ranibizumab) in the US

Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar of Lucentis (ranibizumab) in the US

Shots:

  • Bioeq to receive up front, regulatory and launch milestones with equal profit sharing. Coherus to get exclusive rights to commercialize biosimilar candidate referencing Genentech’s Lucentis with its anticipated launch in 2021 in the US
  • Bioeq will be responsible for product delivery to the Coherus and will submit BLA to the US FDA in Q4’19
  • The biosimilar of Lucentis, being evaluated in P-III study for wet age-related macular degeneration demonstrated bio similarity with the reference product. Bioeq will partner with other companies for its biosimilar ranibizumab outside the US by 2020

Source1, Source 2 to­ read full press release/ article | Ref: Coherus, PRNewswire | Image: Coherus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post